Bibliografía

1. Puech B, Kostrubiec B, Hache J, et al. Epidemiology and prevalence of hereditary retinal dystrophies in the Northern France. J Fr Ophtalmol 1995; 14: 153–64.

2. Nájera C, Millán J, Beneyto M, et al. Epidemiology of retinitis pigmentosa in the Valencian community (Spain). Genet Epidemiol 1995; 12: 37–46.

3. Fundación Retina España. PREVARET: Estudio Epidemiológico Sobre La Prevalencia De Las Enfermedades Distróficas De La Retina. http://retina.es/retina/index.php/informacion-arm-a-fre/proyectos-cientificos/741-prevaret (2012).

4. Fundación Retina España. Principales patologías. Definición y clasificación. Retrieved from http://www.retina.es/retina/index.php/informacion-arm-a-fre/preguntasfrecuentes/240-definicion-y-clasificacion (2010).

5. Delyfer M, Léveillard T, Mohand-Saïd S, et al. Inherited retinal degenerations: therapeutic prospects. Biol Cell 2004; 96: 261–9.

6. Givre S, Gard S. Retinitis pigmentosa: Clinical presentation and diagnosis. UpToDate 2014; 1–12.

7. Sundaram V, Moore A, Ali R, et al. Retinal dystrophies and gene therapy. Eur J Pediatr 2012; 171: 757–65.

8. Sejersen T, Giovane C Del, Filippini G, et al. Methodology for production of best practice guidelines for rare diseases. Rare Dis Orphan Drugs 2014; 1: 10–19.

9. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS, 2007.

10. The AGREE Collaboration. Appraisal of guidelines for research & evaluation (AGREE) instrument. AGREE II Instrument. The Agree Research Trust 2001; 1–20.

11. Grupo de trabajo de implicación de pacientes en el desarrollo de GPC. Implicación de Pacientes en el Desarrollo de Guías de Práctica Clínica: Manual Metodológico. Ministerio de Sanidad, Servicios Sociales e Igualdad. Instituto Aragonés de Ciencias de la Salud-IACS. Guías de Práctica Clínica en el SNS: IACS Nº 2010/01.

12. Serrano-Aguilar P, Trujillo-Martín MM, Pino-Sedeño T, et al. Patient participation in the development of a clinical guideline for inherited retinal dystrophies. Expert Opin Orphan Drugs http://dx.doi.org/10.1080/21678707.2016.1182907 (2016).

13. Guidelines International Network. G-I-N PUBLIC Toolkit: Patient and Public Involvement in Guidelines. 2015; 1–162.

14. GRADE working group. Grading of Recommendations of Assessment Development and Evaluations. Disponible en: http://www.gradeworkinggroup.org/ (accessed 8 February 2016).

15. Shea BJ, Grimshaw JM, Wells G a, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10.

16. Scottish Intercollegiate Guidelines Network. Sign 50 A guideline developer´s handbook. Edinburgh, 2011.

17. Andrews JC, Schünemann HJ, Oxman AD, et al. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol 2013; 66: 726–35.

18. Coco-Martín R, Navarro R, Pinilla I, et al. Guía clínica para el diagnóstico diferencial y el manejo de las enfermedades hereditarias de la retina y la coroides. 2a ed. Madrid: MacLine S.L, 2013.

19. Coco-Martín R, Navarro R, Pinilla I, et al. Enfermedades hereditarias de conos. In: Armadá F, Fonseca A, Encinas J, et al. (eds) Patología y Cirugía de la Mácula. Madrid: MacLine S.L, 2010, pp. 337–356.

20. Rath A. Prevalencia de las enfermedades raras: Datos bibliográficos. Inf Periódicos Orphanet, Ser Enfermedades Raras; Marzo.

21. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006; 1: 40.

22. Bonnet C, El-Amraoui A. Usher syndrome (sensorineural deafness and retinitis pigmentosa): pathogenesis, molecular diagnosis and therapeutic approaches. Curr Opin Neurol 2012; 25: 42–49.

23. Renner AB, Kellner U, Cropp E, et al. Choroideremia: variability of clinical and electrophysiological characteristics and first report of a negative electroretinogram. Ophthalmology 2006; 113: 2066.e1–10.

24. Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis 2007; 2: 7.

25. Ece Solmaz A, Onay H, Atik T, et al. Targeted multi-gene panel testing for the diagnosis of Bardet Biedl syndrome: Identification of nine novel mutations across BBS1, BBS2, BBS4, BBS7, BBS9, BBS10 genes. Eur J Med Genet 2015; 58: 689–694.

26. Fazzi E, Signorini SG, Scelsa B, et al. Leber’s congenital amaurosis: An update. Eur J Paediatr Neurol 2003; 7: 13–22.

27. Coussa RG, Traboulsi EI. Choroideremia: A review of general findings and pathogenesis. Ophthalmic Genet 2012; 33: 57–65.

28. Rubin M. Choroideremia: study of a family and literature review. Arch Ophtalmol 1966; 76: 563–574.

29. Mura M, Sereda C, Jablonski M, et al. Clinical and functional finding in choroideremia due to complete deletion of the CHM gene. Arch Ophtalmol 2007; 125: 1109–1113.

30. Lyon M. Gene action in X chromosome of mouse. Nature 1996; 190: 372–373.

31. Cheung M, Nune G, Wang M, et al. Detection of Localized Retinal Dysfunction in a Choroideremia Carrier. Am J Ophthalmol 2004; 415: 189–191.

32. Furgoch M, Mewes-Arès J, Radziwon A, et al. Molecular genetic diagnostic techniques in choroideremia. Mol Vis 2014; 20: 535–544.

33. Wilson D, Weleber R, Green W. Ocular clinicopathologic study of gyrate atrophy. Am J Ophthalmol 1991; 111: 24–33.

34. Hayasaka S, Shoji K, Kanno C. Differential diagnosis of diffuse choroidal atrophies, diffuse choriocapillaris atrophy, choroideremia, and gyrate atrophy of the choroid and retina. Retina 1985; 5: 30–37.

35. Kurstjens J. Choroideremia and Gyrate atrophy of the choroid and retina. Doc Ophthalmol 1965; 19: 1.

36. Takki K. Gyrate atrophy of the choroid and retina with hyperornithinemia. Br J Ophthalmol 1974; 58: 53.

37. Zeitz C, Robson AG, Audo I. Congenital stationary night blindness: An analysis and update of genotype–phenotype correlations and pathogenic mechanisms. Prog Retin Eye Res 2015; 45: 58–110.

38. Carr R. Congenital stationary nightblindness. Trans Am Ophthalmol Soc 1974; LXXII: 448–487.

39. Watanabe I, Taniguchi Y, Morioka K, et al. Congenital stationary night blindness with myopia: a clinico-pathologic study. Doc Ophthalmol 1986; 63: 55–62.

40. Strom TM, Nyakatura G, Apfelstedt-sylla E, et al. An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness. Nat Genet 1998; 19: 260–263.

41. Rao V, Cohen G, Oprian D. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 1994; 367: 639–642.

42. Ripps H. Night blindness revisited: from man to molecules. Invest Ophthalmol Vis Sci 1982; 23: 588–609.

43. Dryja T, Hahn L, Reboul T, et al. Missense mutation in the gene encoding the a subunit of rod transducin in the Nougaret form of congenital stationary night blindness. Nat Genet 1996; 13: 358–360.

44. Miyake Y, Yagasaki K, Horiguchi M, et al. Congenital Stationary Night Blindness With Negative Electroretinogram. Arch Ophtalmol 1996; 104: 1013–1020.

45. Simunovic M. The cone dystrophies. Eye 1998; 12: 553–565.

46. Thiadens A a HJ, Phan TML, Zekveld-Vroon RC, et al. Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy. Ophthalmology 2012; 119: 819– 826.

47. Neitz J, Neitz M. Color vision defects. In: Jay B, Wright A (eds) Molecular Genetics of Inherited Eye Disorders. New York: Harwood academic publishers, 1994, pp. 2017–257.

48. Coco-Martín R. Enfermedades hereditarias de conos. In: Armadá F, Fonseca A, Encinas J, et al. (eds) Patología y Cirugía de la Mácula. Madrid: Colección Guías de Práctica Clínica de la Sociedad Española de Retina y Vítreo, 2010, pp. 310–355.

49. Walia S, Fishman G a, Molday RS, et al. Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin. Am J Ophthalmol 2009; 147: 111–115.e1.

50. Allikmets R, Singh N, Sun H, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 1997; 15: 236–246.

51. Cideciyan A V, Aleman TS, Swider M, et al. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet 2004; 13: 525–34.

52. Paloma E, Coco R, Martínez-Mir A. Analysis of ABCA4 in mixed Spanish Familias segregating different retinal dystrophies. Hum Mutat 2002; 20: 476–483.

53. Van Driel M, Maugeri A, Klevering B. ABCR unites what ophthalmologist divide. Ophthalmic Genet 1998; 19: 117–122.

54. Gass J. Sterescopic atlas of macular diseases: diagnosis and treatment. 4th ed. St Louis: CV Mosby, 1997.

55. Noble K. Central areolar choroidal dystrophy. Am J Ophthalmol 1977; 84: 310–318.

56. Gamundi MJ, Hernan I, Muntanyola M, et al. High prevalence of mutations in peripherin/RDS in autosomal dominant macular dystrophies in a Spanish population. Mol Vis 2007; 13: 1031–1037.

57. Francois J, De Rouck A, Fernandez-Sasso D. Electro-oculography in vitelliform degeneration of the macula. Arch Ophtalmol 1967; 77: 726–733.

58. Blodi C, Stone E. Best’s vitelliform dystrophy. Ophthalmic Paediatr Genet 1990; 11: 49–59.

59. Petrukhin K, Koisti MJ, Bakall B, et al. Identification of the gene responsible for Best macular dystrophy. Nat Genet 1998; 19: 241–247.

60. Boon CJF, Van Den Born LI, Visser L, et al. Autosomal recessive bestrophinopathy: Differential diagnosis and treatment options. Ophthalmology 2013; 120: 809–820.

61. Boon CJF, Klevering BJ, Leroy BP, et al. The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res 2009; 28: 187–205.

62. Aaberg T, Han D. Evaluation of phenotypic similarities between Stargardt flavimaculatus and retinal pigment epithelial pattern dystrophies. Trans Am Ophthalmol Soc 1987; LXXXV: 101–119.

63. Thomann U, Buchi E, Suppiger M, et al. Age-dependent phenotypic expression of a pattern dystrophy of the retina. Eur J Ophthalmol 1995; 5: 107–112.

64. Coco-Martín R. Distrofias Maculares. In: Armadá F, Fonseca A, Encinas J, et al. (eds) Patología y Cirugía de la Mácula. Madrid: Ponencias de la Sociedad Española de Oftalmología. MacLine S.L, 2010, pp. 337–356.

65. Rose PS, Levy HP, Liberfarb RM, et al. Stickler syndrome: clinical characteristics and diagnostic criteria. Am J Med Genet A 2005; 138A: 199–207.

66. Kim DY, Mukai S. X-linked juvenile retinoschisis (XLRS): a review of genotypephenotype relationships. Semin Ophthalmol 2013; 28: 392–396.

67. Edwards A. Clinical features of the congenital vitreoretinopathies. Eye 2008; 22: 1233– 1242.

68. Bamashmus MA, Downey LM, Inglehearn CF, et al. Genetic heterogeneity in familial exudative vitreoretinopathy ; exclusion of the EVR1 locus on chromosome 11q in a large autosomal dominant pedigree. Br J Ophthalmol 2000; 84: 358–363.

69. Ober R, Bird A, Hamilton A, et al. Autosomal dominant exudative vitreoretinopathy. Br J Ophthalmol 1980; 64: 112–120.

70. Liutkeviciene R, Lesauskaite V, Ašmoniene V, et al. Inherited macular dystrophies and differential diagnostics. Medicina (B Aires) 2012; 48: 485–495.

71. Bravo-Gil N, Méndez-Vidal C, Romero-Pérez L, et al. Improving the management of Inherited Retinal Dystrophies by targeted sequencing of a population-specific gene panel. Sci Rep 2016; 6: 23910.

72. Molday RS, Kellner U, Weber BHF. X-l inked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res 2013; 31: 195–212.

73. Kellner U. Imaging and the perspective of clinical electrophysiology. Doc Ophthalmol 2008; 116: 75–77.

74. Kiser AK, Mladenovich D, Eshraghi F, et al. Reliability and consistency of visual acuity and contrast sensitivity measures in advanced eye disease. Optom Vis Sci 2005; 82: 946– 954.

75. Gerth C, Wright T, Heón E, et al. Assessment of Central Retinal Function in Patients with Advanced Retinitis Pigmentosa. Investig Opthalmology Vis Sci 2007; 48: 1312– 1318.

76. Moloney TP, O’Hagan S, Lee L. Ultrawide-field fundus photography of the first reported case of gyrate atrophy from Australia. Clin Ophthalmol 2014; 8: 1561–3.

77. Furino C, Boscia F, Cardascia N, et al. Fundus autofluorescence, optical coherence tomography and visual acuity in adult-onset foveomacular dystrophy. Ophthalmologica 2008; 222: 240–244.

78. Sunness JS, Steiner JN. Retinal function and loss of autofluorescence in stargardt disease. Retina 2008; 28: 794–800.

79. Oishi A, Ogino K, Makiyama Y, et al. Wide-Field Fundus Autofluorescence Imaging of Retinitis Pigmentosa. Ophthalmology 2013; 120: 1827–1834.

80. Ogura S, Yasukawa T, Kato A, et al. Wide-field fundus autofluorescence imaging to evaluate retinal function in patients with retinitis pigmentosa. Am J Ophthalmol 2014; 158: 1093–8.

81. Mitamura Y, Mitamura-Aizawa S, Nagasawa T, et al. Diagnostic imaging in patients with retinitis pigmentosa. J Med Investig 2012; 59: 1–11.

82. Wabbels B, Demmler A, Paunescu K, et al. Fundus autofluorescence in children and teenagers with hereditary retinal diseases. Graefe’s Arch Clin Exp Ophthalmol 2006; 244: 36–45.

83. Hajali M, Fishman G a, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol 2008; 92: 1065–1068.

84. Oh KT, Weleber RG, Stone EM, et al. Electroretinographic findings in patients with Stargardt disease and fundus flavimaculatus. Retina 2004; 24: 920–928.

85. Iijima H, Yamaguchi S, Kogure S, et al. Electroretinogram in cone dystrophy. Jpn J Ophthalmol 1991; 35: 453–466.

86. Kelly JP, Crognale M a., Weiss AH. ERGs, cone-isolating VEPs and analytical techniques in children with cone dysfunction syndromes. Doc Ophthalmol 2003; 106: 289–304.

87. Makiyama Y, Ooto S, Hangai M, et al. Macular Cone Abnormalities in Retinitis Pigmentosa with Preserved Central Vision Using Adaptive Optics Scanning Laser Ophthalmoscopy. PLoS One 2013; 8: e79447.

88. Tojo N, Nakamura T, Fuchizawa C, et al. Adaptive optics fundus images of cone photoreceptors in the macula of patients with retinitis pigmentosa. Clin Ophthalmol 2013; 7: 203–10.

89. González-del Pozo M, Borrego S, Barragán I, et al. Mutation screening of multiple genes in Spanish patients with autosomal recessive retinitis pigmentosa by targeted resequencing. PLoS One 2011; 6: e27894.

90. Akinci A, Oner O, Aktas Z, et al. Refractive errors and strabismus in children with laurence-moon-biedl syndrome. J Pediatr Ophthalmol Strabismus 2009; 47: 26–28.

91. Iannaccone A, Kritchevsky SB, Ciccarelli ML, et al. Kinetics of visual field loss in Usher syndrome Type II. Invest Ophthalmol Vis Sci 2004; 45: 784–792.

92. Young NM, Mets MB, Hain TC. Early diagnosis of Usher syndrome in infants and children. American Journal of Otology 1996; 17: 30–34.

93. McCulloch DL, Marmor MF, Brigell M, et al. ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 2015; 130: 1–12.

94. Odom JV, Bach M, Brigell M, et al. ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol 2010; 120: 111–119.

95. Hood DC, Bach M, Brigell M, et al. ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 2012; 124: 1–13.

96. Marmor MF, Brigell MG, McCulloch DL, et al. ISCEV standard for clinical electrooculography (2010 update). Doc Ophthalmol 2011; 122: 1–7.

97. Bach M, Brigell MG, Hawlina M, et al. ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Doc Ophthalmol 2013; 126: 1–7.

98. Català J, Castany M. Pruebas electrofisiológicas: ¿qué, cuándo, cómo y por qué? (2a parte). Ann d’Oftalmologia 2005; 13: 76–90.

99. Catala J, Castany M. Pruebas electrofisiológicas: ¿qué, cuándo, cómo y por qué? Ann d’Oftalmologia 2005; 13: 8–29.

100. Brecelj J. Visual electrophysiology in the clinical evaluation of optic neuritis, chiasmal tumours, achiasmia, and ocular albinism: an overview. Doc Ophthalmol 2014; 129: 71– 84.

101. Fishman GA, Birch DG, Holder GE, et al. Electrophysiologic testing in disorders of the retina, optic nerve, and visual pathway. 2 edition. San Francisco: Oxford University Press, 2001.

102. Espinos C, Pérez-Garrigues H, Beneyto M, et al. Sordera hereditaria sindrómica: Síndrome de Usher. An Otorrinolaringol Ibero Am 1999; XXVI: 83–95.

103. Calzada D, Vilela C, Vallet M, et al. Protocolo para la exploración neurofisiológica de los pacientes de retinosis pigmentaria incluidos en los estudios de genética molecular. Rev Neurofisiología Clínica 1993; 6: 157–60.

104. Kriss A, Jeffrey B, Taylor D. The electroretinogram in infants and young children. J Clin Neurophysiol 1992; 9: 373–93.

105. Alonso L, Grimaldos P, Boix J, et al. Study of families with retinitis pigmentosa in the geographic area of valencia (Spain). In: 6th World RP Congress-IRPA-CRC. Press London, 1991, pp. 1–8.

106. Millán J, Martínez F, Vilela C, et al. An autosomal dominant retinitis pigmentosa family with close linkage to D7S480 on 7q. Hum Genet 1995; 96: 216–8.

107. Nájera C, Millán JM, Vilela C, et al. Classification of retinitis pigmentosa in a spanish population on the basis of clinical features and mode of inheritance. Genetic.

108. Burguera J, Vilela C, Vallet M, et al. ERG y PEV en pacientes con la enfermedad de parkinson. Arch Neurobiol 1990; 53: 1–7.

109. Burguera J, Vilela C. The electroretinogram and visual evoked potential in parkinson’s disease. Park Dig 1991; 4: 3–4.

110. Heckenlively JR, G.B.Arden, Nusinowitz S, et al. Principles Practice Clinical Electrophysiology Vision. Masachusetts, London: The Mit Press Cambridge, 2006.

111. Belda J, Romá J, Vilela C, et al. Serum vitamin e levels negatively correlate with severity of age-related macular degeneration. Med Aging Dev.

112. Hawlina M, Konec B. New noncorneal HK-loop electrode for clinical electroretinography. Doc Ophthalmol 1992; 81: 253–9.

113. Marmor MF, Kellner U, Lai TYY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118: 415–422.

114. Bergholz R, Rüther K, Schroeter J, et al. Influence of chloroquine intake on the multifocal electroretinogram in patients with and without maculopathy. Doc Ophthalmol 2015; 130: 211–219.

115. Arden BYGB, Kelsey a DJH. Changes Produced By Light in the Standing. J Physiol 1962; 161: 189–204.

116. Arden GB, Barrada. A. An analysis of the electroculograms of a series of normal subjects. Br J Ophthalmol 1962; 46: 468–82.

117. Arden G, Barrada a, Kelsey J. New clinical test of retinal function based upon the standing potential of the eye. Br J Ophthalmol 1962; 46: 449–467.

118. Koenekoop RK, Lopez I, Den Hollander AI, et al. Genetic testing for retinal dystrophies and dysfunctions: Benefits, dilemmas and solutions. Clin Exp Ophthalmol 2007; 35: 473–485.

119. Lambertus S, Lindner M, Bax NM, et al. Progression of Late-Onset Stargardt Disease. Investig Opthalmology Vis Sci 2016; 57: 5186.

120. Walia S, Fishman G a. Natural history of phenotypic changes in Stargardt macular dystrophy. Ophthalmic Genet 2009; 30: 63–68.

121. Fishman G. Fundus flavimaculatus. A clinical classification. Arch Ophthalmol 1976; 94: 2061–67.

122. Van Huet R a C, Bax NM, Westeneng-Van Haaften SC, et al. Foveal sparing in Stargardt disease. Invest Ophthalmol Vis Sci 2014; 55: 7467–7478.

123. Budiene B, Liutkeviciene R, Zaliuniene D. Best vitelliform macular dystrophy: literature review. Open Med 2014; 784–795.

124. North V, Gelman R, Tsang SH. Juvenile-onset macular degeneration and allied disorders. Dev Ophthalmol 2014; 53: 44–52.

125. Querques G, Zerbib J, Georges A, et al. Multimodal analysis of the progression of Best vitelliform macular dystrophy. Mol Vis 2014; 20: 575–592.

126. Ander G, Gorin MB, Polkinghorne PJ, et al. Detection of the Carrier State of X-Linked Retinoschisis. Am J Ophthalmol 1988; 105: 590–595.

127. Bowles K, Cukras C, Turriff A, et al. X-linked retinoschisis: RS1 mutation severity and age affect the ERG phenotype in a cohort of 68 affected male subjects. Invest Ophthalmol Vis Sci 2011; 52: 9250–9256.

128. Macdonald I, Smaoui N, Seabra M. Choroideremia. In: Pagon R, Adam M, Ardinger H (eds) GeneReviews. Seatle (WA): University of Washington, 2014, pp. 1–12.

129. De Laey J. Leber’s congenital amaurosis. Bull Soc Belge Ophtalmol 1991; 241: 41–50. 130. Seabra M, Brown M, Goldstein J. Retinal degeneration in choroideremia : Deficiency of Rab ge. Science (80- ) 1993; 259: 377–381.

131. Iannaccone A, Vingolo EM, Rispoli E, et al. Electroretinographic alterations in the Laurence-Moon-Bardet-Biedl phenotype. Acta Ophthalmol Scand 1996; 74: 8–13.

132. Smith RJ, Berlin CI, Hejtmancik JF, et al. Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. Am J Med Genet 1994; 50: 32–38.

133. Pakarinen L, Tuppurainen K, Laippala P, et al. The ophthalmological course of Usher syndrome type III. Int Ophthalmol 1996; 19: 307–311.

134. Mets MB, Young NM, Pass a, et al. Early diagnosis of Usher syndrome in children. Trans Am Ophthalmol Soc 2000; 98: 237–242; discussion 243–245.

135. Tamayo ML, Maldonado C, Plaza SL, et al. Neuroradiology and clinical aspects of Usher syndrome. Clin Genet 1996; 50: 126–132.

136. Abraham FA, Cohen D, Sohmer H. Usher’s syndrome: electrophysiological tests of the visual and auditory systems. Doc Ophthalmol 1977; 44: 435–44.

137. Fleischhauer J, Njoh WA, Niemeyer G. Syndromic retinitis pigmentosa: ERG and phenotypic changes. Klin Monbl Augenheilkd 2005; 222: 186–190.

138. Beales P, Elcioglu N, Woolf A, et al. New criteria for improved diagnosis of Bardet- Biedl syndrome: results of a population survey. 1999; 437–446.

139. Saleh SI, Mady S a., Al-Ghanem MM, et al. Bardet-Biedl syndrome: Clinical, endocrinological and imaging evaluation of three unrelated Bedouin children. Med Princ Pract 1998; 7: 230–236.

140. M’hamdi O, Redin C, Stoetzel C, et al. Clinical and genetic characterization of Bardet- Biedl syndrome in Tunisia: Defining a strategy for molecular diagnosis. Clin Genet 2014; 85: 172–177.

141. Dammeyer J. Development and characteristics of children with Usher syndrome and CHARGE syndrome. Int J Pediatr Otorhinolaryngol 2012; 76: 1292–1296.

142. Bande M, Pose S, Treus A, et al. Síndrome de Kearns-Sayre : manifestaciones oftalmológicas. Ann Pediatr 2015; 82: e151–3.

143. Finsterer J, Frank M. Diabetes in Kearns-Sayre Syndrome: More Common than Anticipated. Can J Diabetes 2015; 39: 253.

144. Esteves F, Dolz-Marco R, Hernández-Martínez P, et al. Pattern dystrophy of the macula in a case of steinert disease. Case Rep Ophthalmol 2013; 4: 129–33.

145. Kimizuka Y, Kiyosawa M, Tamai M, et al. Retinal changes in myotonic dystrophy. Clinical and follow-up evaluation. Retina 1993; 13: 1129–35.

146. Sigesmund D, Weleber R, Pillers D, et al. Characterization of the ocular phenotype of Duchenne and Becker muscular dystrophy. Ophthalmology 1994; 101: 856–65.

147. Crane D. Revisiting the neuropathogenesis of Zellweger syndrome. Neurochem Int 2014; 69: 1–8.

148. Folz S, Trobe J. The peroxisome and the eye. Surv Ophthalmol 1991; 35: 353–68.

149. Steinberg S, Raymond G, Braverman N, et al. Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum. In: Pagon R, Adam M, Ardinger H (eds) GeneReviews® [Internet]. Seattle (WA): University of Washington http://www.ncbi.nlm.nih.gov/books/NBK1448/.

150. Rinaldi E, Cotticelli L, Di Meo A, et al. Ocular findings in Refsum’s disease. Metab Pediatr Ophthalmol 1981; 5: 149–54.

151. Grant C a, Berson EL. Treatable forms of retinitis pigmentosa associated with systemic neurological disorders. Int Ophthalmol Clin 2001; 41: 103–10.

152. Hooper A, Burnett J. Update on primary hypobetalipoproteinemia. Curr Atheroscler Rep 2014; 16: 423.

153. Lee J, Hegele R a. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: A framework for diagnosis and management. J Inherit Metab Dis 2014; 37: 333–339.

154. Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol 2014; 25: 161–8.

155. Alshareef R a., Bansal AS, Chiang A, et al. Macular atrophy in a case of abetalipoproteinemia as only ocular clinical feature. Can J Ophthalmol / J Can d’Ophtalmologie 2015; 50: e43–e46.

156. Wong A, Héon E. Helicoid peripapillary chorioretinal degeneration in abetalipoproteinemia. Arch Ophthalmol 1998; 116: 250–1.

157. Duker J, Belmont J, Bosley T. Angioid streaks associated with abetalipoproteinemia. Case report. Arch Ophthalmol 1987; 105: 1173–4.

158. Sperling MA, Hiles DA, Kennerdell JS. Electroretinographic responses following vitamin A therapy in A-beta-lipoproteinemia. Am J Ophthalmol 1972; 73: 342–51.

159. Sirisena ND, Thalgahagoda S, Abeyagunawardena A, et al. Novel COL4A3 gene mutations in a consanguineous family with autosomal recessive Alport syndrome. Nephrology 2015; 20: 580–580.

160. Savige J, Sheth S, Leys A, et al. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol 2015; 10: 703–709.

161. Zylbermann R, Silverstone B, Brandes E, et al. Retinal lesions in Alport’s syndrome. J Pediatr Ophthalmol Strabismus 1980; 17: 255–60.

162. Sohar E. A heredo-familial syndrome characterized by renal disease, inner ear deafness, and ocular changes. Harefuah 1954; 47: 161–2.

163. Sjögren T, Larsson T. Oligophrenia in combination with congenital ichthyosis and spastic disorders; a clinical and genetic study. Acta Psychiatr Neurol Scand 1957; 113: 1–112.

164. Sanabria MR, Coco RM. Sjögren-Larsson Syndrome. Ophthalmology 2011; 118: 2101– 2102.

165. Lund C, Bjørnvold M, Tuft M, et al. Aicardi syndrome: an epidemiologic and clinical study in Norway. Pediatr Neurol 2015; 52: 182–6.e3.

166. Martel JN, Rutar T, Lujan BJ, et al. Chorioretinal architecture in Aicardi syndrome: an optical coherence tomography and fluorescein angiography study. J AAPOS 2011; 15: 308–10.

167. Guerriero S, Sciruicchio V, De Blasi R, et al. Chorioretinal lacunae: pathognomonic findings for Aicardi syndrome. J Pediatr Ophthalmol Strabismus 2010; 21: e1–3.

168. Nowak V, Bremner F, Massey L, et al. Kjellin syndrome: hereditary spastic paraplegia with pathognomonic macular appearance. Pr Neurol 2014; 14: 278–9.

169. Farmer S, Longstreth WJ, Kalina R, et al. Fleck retina in Kjellin’s syndrome. Am J Ophthalmol 1985; 99: 45–50.

170. Tarantola RM, Nguyen V, Agarwal A. Characterization of Kjellin Syndrome using Spectral-Domain Optical Coherence Tomography and Fundus Autofluorescence. Retin Cases Br Reports 2011; 5: 49–55.

171. Puech B, Lacour A, Stevanin G, et al. Kjellin syndrome: long-term neuroophthalmologic follow-up and novel mutations in the SPG11 gene. Ophthalmology 2011; 118: 564–73.

172. Suzuki T, Miyake N, Tsurusaki Y, Okamoto N, Alkindy A, Inaba A, Sato M, Ito S, Muramatsu K, Kimura S, Ieda D, Saitoh S, Hiyane M, Suzumura H, Yagyu K, Shiraishi H, Nakajima M, Fueki N, Habata Y, Ueda Y, Komatsu Y, Yan K, Shimoda K, Shitara Y, Mizuno S, Ic MN. Molecular genetic analysis of 30 families with Joubert syndrome. Clin Genet 2016; 1–11.

173. Adams N a, Awadein A, Toma HS. The retinal ciliopathies. Ophthalmic Genet 2007; 28: 113–25.

174. Brancati F, Dallapiccola B, Valente EM. Joubert Syndrome and related disorders. Orphanet J Rare Dis 2010; 5: 20.

175. Valente E, Dallapiccola B, Bertini E. Joubert syndrome and related disorders. Handb Clin Neurol 2013; 113: 1879–88.

176. Knopp C, Rudnik-Schöneborn S, Eggermann T, et al. Syndromic ciliopathies: From single gene to multi gene analysis by SNP arrays and next generation sequencing. Mol Cell Probes 2015; 29: 299–307.

177. Álvarez-Satta M, Castro-sánchez S, Valverde D. Alström syndrome : current perspectives. Appl Clin Genet 2015; 8: 171–179.

178. Stone E, Ho CY. Genetic testing for inherited heart disease. Arch Ophtalmol 2007; 125: 205–212.

179. O’Sullivan J, Mullaney BG, Bhaskar SS, et al. A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J Med Genet 2012; 49: 322–326.

180. Heon E. Predictive DNA testing in ophthalmology: View 1. Br J Ophthalmol 2003; 87: 633–635.

181. MacDonald IM, Tran M, Musarella MA. Ocular genetics: current understanding. Surv Ophthalmol 2004; 49: 159–196.

182. Ministerios de Sanidad SS e I. Orden SSI/2065/2014, de 31 de octubre, por la que se modifican los anexos I, II y III del Real Decreto 1030/2006, de 15 de septiembre, por el que se establece la cartera de servicios comunes del Sistema Nacional de Salud y el procedimiento para su actuali. 2014.

183. Alapati A, Goetz K, Suk J, et al. Molecular diagnostic testing by eyeGENE: analysis of patients with hereditary retinal dystrophy phenotypes involving central vision loss. Invest Ophthalmol Vis Sci 2004; 31: 15510–5521.

184. Combs R, McAllister M, Payne K, et al. Understanding the impact of genetic testing for inherited retinal dystrophy. Eur J Hum Genet 2013; 21: 1–5.

185. Eden M, Payne K, Combs RM, et al. Valuing the benefits of genetic testing for retinitis pigmentosa: a pilot application of the contingent valuation method. Br J Ophthalmol 2013; 97: 1051–1056.

186. Mackey D, Heon E, Webster A. Predictive DNA testing in ophthalmology: View 2. Br J Ophthalmol 2003; 87: 633.

187. Wiggs J, Pierce E. Genetic testing for inherited eye disease: who benefits? JAMA Ophthalmol 2013; 131: 9–10.

188. Sutherland JE, Day M a. Advantages and disadvantages of molecular testing in ophthalmology. Expert Rev Ophthalmol 2011; 6: 221–245.

189. Zanolli MT, Khetan V, Dotan G, et al. Should patients with ocular genetic disorders have genetic testing? Curr Opin Ophthalmol 2014; 25: 359–365.

190. Stroh E. Taking the family history in genetic disease. Curr Opin Ophthalmol 2011; 22: 340–346.

191. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res 2010; 29: 335–375.

192. Downs K, Zacks DN, Caruso R, et al. Molecular testing for hereditary retinal disease as part of clinical care. Arch Ophthalmol 2007; 125: 252–258.

193. Wang DY, Chan WM, Tam POS, et al. Gene mutations in retinitis pigmentosa and their clinical implications. Clin Chim Acta 2005; 351: 5–16.

194. Fan BJ, Tam POS, Choy KW, et al. Molecular diagnostics of genetic eye diseases. Clin Biochem 2006; 39: 231–239.

195. Evans K, Gregory CY, Er AFRY, et al. The role of molecular genetics in the prenatal diagnosis of retina l dystrophies. Eye 1995; 9: 24–28.

196. Wang F, Wang H, Tuan H-F, et al. Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: identification of a novel genotype-phenotype correlation and clinical refinements. Hum Genet 2014; 133: 331–345.

197. Corton M, Nishiguchi KM, Avila-Fernández A, et al. Exome Sequencing of Index Patients with Retinal Dystrophies as a Tool for Molecular Diagnosis. PLoS One 2013; 8: e65574.

198. Fu Q, Wang F, Wang H, et al. Next-Generation Sequencing–Based Molecular Diagnosis of a Chinese Patient Cohort With Autosomal Recessive Retinitis Pigmentosa. Investig Opthalmology Vis Sci 2013; 54: 4158.

199. Golovleva I, Köhn L, Burstedt M, et al. Retinal Degenerative Diseases. 2010; 664: 1–6.

200. Li S, Shen T, Xiao X, et al. Detection of CRB1 mutations in families with retinal dystrophy through phenotype-oriented mutational screening. Int J Mol Med 2014; 913– 918.

201. Audo I, Bujakowska KM, Leveillard T, et al. Development and application of a nextgeneration- sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases. Orphanet J Rare Dis 2012; 7: 8.

202. Thiadens A, Klaver C. Genetic Testing and Clinical Characterization of Patients with Cone-Rod Dystrophy. Invest Ophthalmol Vis Sci 2010; 51: 6904–6905.

203. Fujinami K, Zernant J, Chana RK, et al. ABCA4 Gene Screening by Next-Generation Sequencing in a British Cohort. Investig Opthalmology Vis Sci 2013; 54: 6662.

204. Drenser KA, Dailey W, Vinekar A, et al. Clinical presentation and genetic correlation of patients with mutations affecting the FZD4 gene. Arch Ophthalmol 2009; 127: 1649– 1654.

205. Bhatti MT. Retinitis pigmentosa, pigmentary Retinopathies, and Neurologic Diseases.

206. Jaijo T, Aller E, Beneyto M, et al. Estudio genético molecular del síndrome de Usher en España. 2005; 1: 285–289.

207. McKibbin M, Ahmed M, Allsop MJ, et al. Current understanding of genetics and genetic testing and information needs and preferences of adults with inherited retinal disease. Eur J Hum Genet 2014; 22: 1058–1062.

208. Forsythe E, Beales PL. Bardet–Biedl syndrome. Eur J Hum Genet 2013; 21: 8–13.

209. Scanga HL, Nischal KK. Genetics and Ocular Disorders. Pediatr Clin North Am 2014; 61: 555–565.

210. Wang X, Wang H, Sun V, et al. Comprehensive molecular diagnosis of 179 Leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next generation sequencing. J Med Genet 2013; 50: 674–688.

211. Khan A, Al-Mesfer S, Al-Turkmani S, et al. Genetic analysis of strictly defined Leber congenital amaurosis with (and without) neurodevelopmental delay. Br J Ophthalmol 2014; 98: 1724–1728.

212. Hanein S, Perrault I, Gerber S, et al. Leber congenital amaurosis: Comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotypephenotype correlations as a strategy for molecular diagnosis. Hum Mutat 2004; 23: 306– 317.

213. Stone E. Leber Congenital Amaurosis–A Model for Efficient Genetic Testing of Heterogeneous Disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol 2007; 144: 791–811.

214. Chan S, Freund PR, MacDonald I. Advances in the genetics of eye diseases. Curr Opin Pulm Med 2013; 25: 645–52.

215. Gillespie RL, Hall G, Black GC. Genetic testing for inherited ocular disease: delivering on the promise at last? Clin Experiment Ophthalmol 2014; 42: 65–77.

216. Mezer E, Sutherland J, Goei SL, et al. Utility of molecular testing for related retinal dystrophies. Can J Ophthalmol / J Can d’Ophtalmologie 2006; 41: 190–196.

217. Pradhan M, Hayes I, Vincent A. An audit of genetic testing in diagnosis of inherited retinal disorders: a prerequisite for gene-specific intervention. Clin Experiment Ophthalmol 2009; 37: 703–711.

218. Goodwin P. Hereditary retinal disease. Curr Opin Ophthalmol 2008; 19: 255–262.

219. Shanks ME, Downes SM, Copley RR, et al. Next-generation sequencing (NGS) as a diagnostic tool for retinal degeneration reveals a much higher detection rate in earlyonset disease. Eur J Hum Genet 2013; 21: 274–280.

220. Chang S, Vaccarella L, Olatunji S, et al. Diagnostic challenges in retinitis pigmentosa: genotypic multiplicity and phenotypic variability. Curr Genomics 2011; 12: 267–75.

221. Ruddle J. Gene testing for the next generation. Clin Experiment Ophthalmol 2014; 42: 1–1.

222. Sutherland J, Day M. Genetic counseling and genetic testing in ophthalmology. Curr Opin Ophthalmol 2009; 20: 343–350.

223. Ernest PJG, Boon CJF, Klevering BJ, et al. Outcome of ABCA4 microarray screening in routine clinical practice. Mol Vis 2009; 15: 2841–7.

224. Clark GR, Crowe P, Muszynska D, et al. Development of a Diagnostic Genetic Test for Simplex and Autosomal Recessive Retinitis Pigmentosa. Ophthalmology 2010; 117: 2169–2177.e3.

225. Neveling K, Collin RWJ, Gilissen C, et al. Next-generation genetic testing for retinitis pigmentosa. Hum Mutat 2012; 33: 963–972.

226. Zaneveld J, Wang F, Wang X, et al. Dawn of ocular gene therapy: Implications for molecular diagnosis in retinal disease. Sci China Life Sci 2013; 56: 125–133.

227. Daiger S, Sullivan L, Bowne S. Genes and mutations causing retinitis pigmentosa. Clin Genet 2013; 84: 1–16.

228. Anasagasti A, Irigoyen C, Barandika O, et al. Current mutation discovery approaches in Retinitis Pigmentosa. Vision Res 2012; 75: 117–129.

229. Willis T, Potrata B, Ahmed M, et al. Understanding of and attitudes to genetic testing for inherited retinal disease: a patient perspective. Br J Ophthalmol 2013; 97: 1148–1154.

230. Bong C, Potrata B, Hewison J, et al. Attitudes of patients and relatives/carers towards genetic testing for inherited retinal disease. Eye (Lond) 2010; 24: 1622–1625.

231. Kimberling WJ, Hildebrand MS, Shearer a E, et al. Frequency of Usher Syndrome in Two Pediatric Populations: Implications for genetic screening of Deaf and Hard of Hearing Children. Genet Med 2011; 12: 512–516.

232. Jefatura del Estado. Ley 14/2007, de 3 de julio, de Investigación biomédica. 2007.

233. Branham K, Yashar BM. Providing comprehensive genetic-based ophthalmic care. Clin Genet 2013; 84: 183–189.

234. Schwartz M, Rosenberg T. Prenatal diagnosis of choroidemia. Acta Ophthalmol Scand 1996; 74: 33–6.

235. Mackey D. -Overview. Predictive DNA testing in ophthalmology. Br J Ophthalmol 2003; 87: 637–8.

236. Potrata B, McKibbin M, Lim JN, et al. ‘To perpetuate blindness!’: attitudes of UK patients with inherited retinal disease towards genetic testing. J Community Genet 2014; 5: 215–22.

237. Ayuso C, Dal-Ré R. Comunicación de los resultados a los participantes en la investigación genética de las enfermedades raras. In: Ayuso C, Dal-Ré R, Palau F (eds) Ética en la investigación de las enfermedades raras. Madrid: Ergon, 2016, pp. 57–73.

238. Ministerio de Sanidad y Política Social. Cartera de servicios comunes del Sistema Nacional de Salud y procedimiento para su actualización.

239. Grover S, Fishman G a, Brown J. Patterns of visual field progression in patients with retinitis pigmentosa. Ophthalmology 1998; 105: 1069–1075.

240. Flynn MF, Fishman G a, Anderson RJ, et al. Retrospective longitudinal study of visual acuity change in patients with retinitis pigmentosa. Retina 2001; 21: 639–646.

241. Genead M a, Fishman G a. Cystic macular oedema on spectral-domain optical coherence tomography in choroideremia patients without cystic changes on fundus examination. Eye (Lond) 2011; 25: 84–90.

242. Roberts MF, Fishman G a, Roberts DK, et al. Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia. Br J Ophthalmol 2002; 86: 658–662.

243. Nagy D, Schönfisch B, Zrenner E, et al. Long-term follow-up of retinitis pigmentosa patients with multifocal electroretinography. Invest Ophthalmol Vis Sci 2008; 49: 4664– 71.

244. Wolsley CJ, Silvestri G, O’Neill J, et al. The association between multifocal electroretinograms and OCT retinal thickness in retinitis pigmentosa patients with good visual acuity. Eye 2009; 23: 1524–1531.

245. Ikenoya K, Kondo M, Piao C-H, et al. Preservation of macular oscillatory potentials in eyes of patients with retinitis pigmentosa and normal visual acuity. Invest Ophthalmol Vis Sci 2007; 48: 3312–7.

246. Berson E, Sandberg M, Rosner B, et al. Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol 1985; 99: 240–51.

247. Holopigian K, Greenstein V, Seiple W, et al. Rates of change differ among measures of visual function in patients with retinitis pigmentosa. Ophthalmology 1996; 103: 398– 405.

248. Takki KK, Milton RC. The natural history of gyrate atrophy of the choroid and retina. Ophthalmology 1981; 88: 292–301.

249. Kaiser-Kupfer M, Kuwabara T, Askanas V. Systemic manifestations of gyrate atrophy of the choroid and retina. Ophthalmology 1981; 88: 302–6.

250. Freund PR. The natural history and genotypes of choroideremia. University of Alberta. Epub ahead of print 2014. DOI: 10.1007/s13398-014-0173-7.2.

251. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006; 368: 1795–809.

252. Berson EL. Retinitis pigmentosa: The Friedenwald lecture. Investig Ophthalmol Vis Sci 1993; 34: 1659–1676.

253. MacDonald I, Hume S, Chan S, et al. Choroideremia. In: Pagon R, Adam M, Ardinger H (eds) GeneReviews® [Internet]. Seattle (WA): University of Washington http://www.ncbi.nlm.nih.gov/books/NBK1337/ (2003).

254. Rubin M, Fishman R, McKay R. Choroideremia. Study of a family and literature review. Arch Ophthalmol 1966; 76: 563–74.

255. Berson E. Electroretinographic findings in retinitis pigmentosa. Jpn J Ophthalmol 1987; 31: 327–48.

256. Joint Committee on Infant Hearing. Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. Pediatrics 2007; 120: 898–921.

257. Trinidad-Ramos G, de Aguilar VA, Jaudenes-Casaubón C, et al. Recomendaciones de la comision para la deteccion precoz de la hipoacusia (CODEPEH) para 2010. Acta otorrinolaringológica española 2010; 61: 69–77.

258. Jatana K, Thomas D, Weber L. Usher Syndrome: Characteristics and Outcomes of Pediatric Cochlear Implant Recipients. Otol … 2013; 34: 484–489.

259. Iwasaki S, Maruyama Y, Hotta Y, et al. Survey in to the prevalence of hearing loss in patients diagnosed with retinitis pigmentosa. Int Ophthalmol 2004; 25: 277–282.

260. Pennings R, Huygen P, Weston M, et al. Pure tone hearing thresholds and speech recognition scores in Dutch patients carrying mutations in the USH2A gene. Otol Neurotol 2003; 24: 58–63.

261. Teschner M, Neuburger J, Gockeln R, et al. ‘Minimized rotational vestibular testing’ as a screening procedure detecting vestibular areflexy in deaf children: screening cochlear implant candidates for Usher syndrome type I. Eur Arch Oto-Rhino-Laryngology 2008; 265: 759–763.

262. Bamiou DE, Spraggs PRD, Gibberd FB, et al. Hearing loss in adult Refsum’s disease. Clin Otolaryngol Allied Sci 2003; 28: 227–230.

263. Lamont P, Surtees R, Woodward C, et al. Clinical and laboratory findings in referrals for mitochondrial DNA analysis. Arch Dis Child 1998; 79: 22–27.

264. Marr JE, Halliwell-Ewen J, Fisher B, et al. Associations of high myopia in childhood. Eye 2001; 15: 70–74.

265. Logan NS, Gilmartin B, Marr JE, et al. Community-based study of the association of high myopia in children with ocular and systemic disease. Optom Vis Sci 2004; 81: 11– 13.

266. Riise R. Visual function in Laurence-Moon-Bardet-Biedl syndrome. A survey of 26 cases. Acta Ophthalmol Suppl 1987; 182: 128–131.

267. Russell-Eggitt M, Clayton PT, Kriss A, et al. Alstrom Syndrome Report of 22 Cases and Literature Review. Ophthalmology 1998; 105: 1274–1280.

268. Fleischhauer J, Njoh W, Niemeyer G. Syndromic retinitis pigmentosa: ERG and phenotypic changes. Klin Monbl Augenheilkd 2005; 222: 186–190.

269. Gerth C, Morel CF, Feigenbaum A, et al. Ocular phenotype in patients with methylmalonic aciduria and homocystinuria, cobalamin C type. J AAPOS 2008; 12: 591– 6.

270. Collins J, Holder GE, Herbert H, et al. Batten disease: features to facilitate early diagnosis. Br J Ophthalmol 2006; 90: 1119–1124.

271. Dulz S, Wagenfeld L, Nickel M, et al. Novel morphological macular findings in juvenile CLN3 disease. Br J Ophthalmol 2005; in press.

272. Francis JH, Rao L, Rosen RB. Methylmalonic aciduria and homocystinuria-associated maculopathy. Eye (Lond) 2010; 24: 1731–2.

273. Ticho B, Feist R, Fishman G. Nondetectable electroretinogram in combined methylmalonic aciduria and homocystinuria. Ann Ophthalmol 1992; 24: 180–1.

274. Tsina E, Marsden D, Hansen R, et al. Maculopathy and retinal degeneration in Cobalamin C methylmalonic aciduria and homocystinuria. Arch Ophthalmol 2005; 123: 1143–6.

275. Martínez M. Clinical symptoms of generalized peroxisomal disorders. Rev Neurol 1999; 28: S49–54.

276. Margaron P, Castaner L, Narfström K. Evaluation of Intravitreal -Retinoid Replacement Therapy in a Canine Model of Leber’s Congenital Amaurosis. ARVO http://www.qltinc.com/development/products/documents/ARVO2009Poster.pdf (2009).

277. Merin S, Obolensky A, Farber MD, et al. A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther 2008; 24: 80– 86.

278. Pasantes-Morales H, Quiroz H, Quesada O. Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: A 3-year follow-up study. Metab Brain Dis 2002; 17: 183–197.

279. Nano H. Tratamiento de la retinosis pigmentaria con raubasina. Prensa Med Argent 1977; 64: 52–54.

280. Clemson CM, Tzekov R, Krebs M, et al. Therapeutic potential of valproic acid for retinitis pigmentosa. Br J Ophthalmol 2011; 95: 89–93.

281. Bhalla S, Joshi D, Bhullar S, et al. Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. Br J Ophthalmol 2013; 97: 895–9.

282. Kumar A, Midha N, Gogia V, et al. Efficacy of Oral Valproic Acid in Patients with Retinitis Pigmentosa. J Ocul Pharmacol Ther 2014; 30: 580–586.

283. Akiyama M, Ikeda Y, Yoshida N, et al. Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa. Acta Ophthalmol 2014; 92: e229–e234.

284. Tawada A, Sugawara T, Ogata K, et al. Improvement of central retinal sensitivity six months after topical isopropyl unoprostone in patients with retinitis pigmentosa. Indian J Ophthalmol 2013; 61: 95–9.

285. Gahlot DK, Sood VP, Khosla PK. Effect of penicillamine on the sensori-neural deafness of retinitis pigmentosa. J Laryngol Otol 1977; 91: 1107–1111.

286. Gahlot DK. Penicillamine-A new therapy of retinitis pigmentosa. Indian J Ophthalmol 1981; 29: 355–358.

287. Greenstein VC, Holopigian K, Siderides E, et al. The effects of acetazolamide on visual function in retinitis pigmentosa. Investig Ophthalmol Vis Sci 1993; 34: 269–273.

288. Katznelson LA, Khoroshilova-Maslova IP, Eliseyeva RF. A new method of treatment of retinitis pigmentosa/pigmentary abiotrophy. Ann Ophthalmol 1990; 22: 167–172.

289. Nakazawa M, Ohguro H, Takeuchi K, et al. Effect of nilvadipine on central visual field in retinitis pigmentosa: A 30-month clinical trial. Ophthalmologica 2011; 225: 120–126.

290. Nakazawa M, Suzuki Y, Ito T, et al. Long-Term Effects of Nilvadipine against Progression of the Central Visual Field Defect in Retinitis Pigmentosa : An Extended Study. Hindawi Publ Corp 2013; 2013: ID 585729.

291. Newsome D, Dorsey F, May J, et al. Glanglioside administration in retinitis pigmentosa. J Ocul Pharmacol 1987; 3: 323–332.

292. Birch D, Weleber R, Duncan J, et al. Randomized trial of ciliary neurotrophic factor deliveresd by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol 2013; 156: 283–292.

293. Talcott KE, Ratnam K, Sundquist SM, et al. Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci 2011; 52: 2219–26.

294. Pilli S, Zawadzki RJ, Telander DG. The dose-dependent macular thickness changes assessed by FD-OCT in patients with retinitis pigmentosa treated with ciliary neurotrophic factor. Retina 2014; 34: 1384–1390.

295. Palanker D, Vankov A, Huie P, et al. Design of a high-resolution optoelectronic retinal prosthesis. J Neural Eng 2005; 2: S105–20.

296. Huang Q, Chowdhury V, Coroneo MT. Evaluation of patient suitability for a retinal prosthesis using structural and functional tests of inner retinal integrity. J Neural Eng 2009; 6: 35010.

297. Fernandes R a B, Diniz B, Ribeiro R, et al. Artificial vision through neuronal stimulation. Neurosci Lett 2012; 519: 122–128.

298. Chow AY, Chow VY, Packo KH, et al. The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa. Arch Ophthalmol 2004; 122: 460–469.

299. Yanai D, Weiland JD, Mahadevappa M, et al. Visual Performance Using a Retinal Prosthesis in Three Subjects With Retinitis Pigmentosa. Am J Ophthalmol; 143. Epub ahead of print 2007. DOI: 10.1016/j.ajo.2007.01.027.

300. Klauke S, Goertz M, Rein S, et al. Stimulation with a wireless intraocular epiretinal implant elicits visual percepts in blind humans. Investig Ophthalmol Vis Sci 2011; 52: 449–455.

301. Dorn J, Ahuja A, Caspi A, et al. The detection of motion by blinf subjects with the epiretinal 60-electrode (argus II) retinal prothesis. JAMA Ophthalmol 2013; 131: 183– 189.

302. Chow AY, Bittner AK, Pardue MT. The artificial silicon retina in retinitis pigmentosa patients (an American Ophthalmological Association thesis). Trans Am Ophthalmol Soc 2010; 108: 120–154.

303. Vaidya A, Borgonovi E, Taylor RS, et al. The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. BMC Ophthalmol 2014; 14: 49.

304. Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. Valor Monetario de un Año de Vida Ajustado por Calidad: Estimación empírica del coste de oportunidad en el Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud, 2015.

305. M.F. D, D.a. W, P. K, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007; 23: 36–42.

306. Das T, Cerro M, Jalali S, et al. Das T. Exp Neurol. 1999.pdf. 1999; 68: 58–68.

307. Radtke ND, Aramant RB, Seiler M, et al. Preliminary report: Indications of improved visual function after retinal sheet transplantation in retinitis pigmentosa patients. Am J Ophthalmol 1999; 128: 384–387.

308. Humayun MS, De Juan E. J, Del Cerro M, et al. Human neural retinal transplantation. Investig Ophthalmol Vis Sci 2000; 41: 3100–3106.

309. Radtke ND, Seiler MJ, Aramant RB, et al. Transplantation of intact sheets of fetal neural retina with its retinal pigment epithelium in retinitis pigmentosa patients. Am J Ophthalmol 2002; 133: 544–550.

310. Berger AS, Tezel TH, Del Priore L V., et al. Photoreceptor transplantation in retinitis pigmentosa: Short-term follow-up. Ophthalmology 2003; 110: 383–391.

311. Park SS, Bauer G, Abedi M, et al. Intravitreal Autologous Bone Marrow CD34+ Cell Therapy for Ischemic and Degenerative Retinal Disorders: Preliminary Phase 1 Clinical Trial Findings. Invest Ophthalmol Vis Sci 2014; 56: 81–89.

312. Siqueira RC, Messias A, Voltarelli JC, et al. Intravitreal Injection of Autologous Bone Marrow–Derived Mononuclear Cells for Hereditary Retinal Dystrophy. Retina 2011; 31: 1207–1214.

313. Radtke ND, Aramant RB, Petry HM, et al. Vision Improvement in Retinal Degeneration Patients by Implantation of Retina Together with Retinal Pigment Epithelium. Am J Ophthalmol; 146. Epub ahead of print 2008. DOI: 10.1016/j.ajo.2008.04.009.

314. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: Follow-up of two open-label phase 1/2 studies. Lancet 2015; 385: 509–516.

315. Schwartz SD, Hubschman J, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012; 379: 713–720.

316. Van Hooser JP, Aleman TS, He YG, et al. Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness. Proc Natl Acad Sci U S A 2000; 97: 8623–8628.

317. Acland G, Aguirre G, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92–5.

318. Jacobson SG, Cideciyan A V, Ratnakaram R, et al. Gene Therapy for Leber Congenital Amaurosis caused by RPE65 mutations: Safety and Efficacy in Fifteen Children and Adults Followed up to Three Years. Arch Ophthalmol 2012; 130: 9–24.

319. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 8: 120.

320. Weleber RG, Pennesi ME, Wilson DJ, et al. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. Ophthalmology 2015; 123: 1606–1620.

321. Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 2008; 358: 2231–39.

322. Bainbridge J, Mehat M, Sundaram V, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med 2015; 372: 1887–97.

323. MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014; 383: 1129– 37.

324. LaVail M, Yasumura D, Matthes M, et al. Gene Therapy for MERTK-Associated Retinal Degenerations. Adv Exp Med Biol 2016; 854: 487–493.

325. Ghazi N, Abboud E, Nowilaty S, et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. H. Hum Genet 2016; 135: 327–343.

326. Ye G, Budzynski E, Sonnentag P, et al. Safety and Biodistribution Evaluation of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin, in RS1-Deficient Mice. Hum Gene Ther Clin Dev; 26.

327. Bush RA, Yong Z, Peter C, et al. Preclinical Dose-Escalation Study of Intravitreal AAVRS1 Gene Therapy in a Mouse Model of X-linked Retinoschisis: Dose-Dependent Expression and Improved Retinal Structure and Function. Hum Gene Ther 2016; 27: 376–389.

328. Ye G, Budzynski E, Sonnentag P, et al. Safety and Biodistribution Evaluation in CNGB3-deficient Mice of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia. Hum Gene Ther Clin Dev; 7.

329. Ye G, Budzynski E, Sonnentag P, et al. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia. Hum Gene Ther Clin Dev; 8.

330. Binley K, Widdowson P, Loader J, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: Safety and biodistribution of stargen for stargardt disease. Investig Ophthalmol Vis Sci 2013; 54: 4061–4071.

331. Han Z, Conley S, Naash M. Gene therapy for Stargardt disease associated with ABCA4 gene. Adv Exp Med Biol 2014; 801: 719–724.

332. Trapani I, Toriello E, De Simone S, et al. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum Mol Genet 2015; 24: 6811–6825.

333. Zallocchi M, Binley K, Lad Y, et al. EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: Development of UshStat. PLoS One; 9. Epub ahead of print 2014. DOI: 10.1371/journal.pone.0094272.

334. Rayapudi S, Schwartz S, Wang X, et al. Vitamin A and fish oils for retinitis pigmentosa. Cochrane Database Syst Rev 2013; 12: CD008428.

335. Berson E, Rosner B, Sandberg M, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993; 111: 761–72.

336. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004; 122: 1306–14.

337. Berson EL, Rosner B, Sandberg MA, et al. Further Evaluation of Docosahexaenoic Acid in Patients With Retinitis Pigmentosa Receiving Vitamin A Treatment. Arch Ophthalmol 2004; 122: 1306–14.

338. Radu R a, Yuan Q, Hu J, et al. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following vitamin a supplementation. Invest Ophthalmol Vis Sci 2008; 49: 3821–3829.

339. Charbel Issa P, Barnard AR, Herrmann P, et al. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci 2015; 112: 8415–20.

340. Chowers I, Banin E, Merin S, et al. Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipo-proteinaemia patients. Eye 2001; 15: 525–30.

341. Kennaway NG, Weleber RG, Buist NR. Gyrate atrophy of the choroid and retina with hyperornithinemia: biochemical and histologic studies and response to vitamin B6. Am J Hum Genet 1980; 32: 529–541.

342. Weleber RG, Kennaway NG. Clinical Trial of Vitamin B6 for Gyrate Atrophy of the Choroid and Retina. Ophthalmology 1981; 88: 316–24.

343. Berson E, Rosner B, Sandberg M, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993; 111: 761–72.

344. Massof RW, Fishman G a. How strong is the evidence that nutritional supplements slow the progression of retinitis pigmentosa? Arch Ophthalmol 2010; 128: 493–495.

345. Snodgrass S. Vitamin neurotoxicity. Mol Neurobiol 1992; 6: 41–73.

346. Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol 1999; 63: 139–88.

347. Rutkowski M, Grzegorczyk K. Adverse effects of antioxidative vitamins. Int J Occup Med Environ Health 2012; 25: 105–121.

348. Kapil U. Time to stop giving indiscriminate massive doses of synthetic vitamin A to Indian children. Public Health Nutr 2009; 12: 285.

349. Penniston KL, Tanumihardjo S. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr 2006; 83: 191–201.

350. Allen H, Haskell M. Estimating the potentual for vitamin A toxicity in women and young children. J Nutr 2002; 132: 2907–19S.

351. Lam H, Chow C, Poon W, et al. Risk of vitamin A toxicity from candy-like chewable vitamin supplements for children. Pediatrics 2006; 118: 820–4.

352. Olson J. Vitamin A. Present Knowledge in Nutrition. In: Present Knowledge in Nutrition. Washington, DC: The Nutrition Foundation, 1993, pp. 176–91.

353. Lawson J, McGuire J. The spectrum of skeletal changes associated with long-term administration of 13-cis-retinoic acid. Skelet Radiol 1987; 16: 91–7.

354. Geubel A, De Galocsy C, Alves N, et al. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 1991; 100: 1701–9.

355. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancer of the skin. N Engl J Med 1990; 323: 789–95.

356. Oliveira MR De. The neurotoxic effects of vitamin A and retinoids. 2015; 87: 1361– 1373.

357. Alpers DH. Vitamins as drugs: the importance of pharmacokinetics in oral dosing. Curr Opin Gastroenterol 2011; 27: 146–51.

358. Halliwell B. Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutr Rev 1999; 57: 104–13.

359. European Food Safety Authority. Tolerable Upper Intake Levels Scientific Committee on Food Scientific Panel on Dietetic Products, Nutrition and Allergies. 2006.

360. Food and Nutrition Board I of M. Vitamin A. In: Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington D.C.: National Academy Press, 2001, pp. 65–126.

361. Hoffman DR, Locke KG, Wheaton DH, et al. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol 2004; 137: 704–18.

362. Hoffman DR, Hughbanks-Wheaton DK, Pearson NS, et al. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA Ophthalmol 2014; 132: 866–73.

363. Lee TKM, Clandinin MT, Hébert M, et al. Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial. Can J Ophthalmol 2010; 45: 514–9.

364. Bahrami H, Melia M, Dagnelie G. Lutein supplementation in retinitis pigmentosa : PCbased vision assessment in a randomized double-masked placebo-controlled. BCM Ophthalmol 2006; 6: 23.

365. Dagnelie G, Melia B, Sunness J. Lutein supplementation in RP: Vision measures in the clinic. Invest Ophthalmol Vis Sci 2003; 44: 780.

366. Berson E, Rosner B, Sandberg M, et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 2010; 128: 403–11.

367. Dagnelie G, Zorge IS, McDonald TM. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Optometry 2000; 71: 147–64.

368. Aleman TS, Duncan JL, Bieber ML, et al. Macular Pigment and Lutein Supplementation in Retinitis Pigmentosa and Usher Syndrome. Inves Ophtalmol Vis … 2001; 42: 1873– 81.

369. Dagnelie G, Zorge I, McDonald T. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Optometry 2000; 71: 147–64.

370. Aleman TS, Cideciyan A V., Windsor EAM, et al. Macular pigment and lutein supplementation in ABCA4-associated retinal degenerations. Investig Ophthalmol Vis Sci 2007; 48: 1319–1329.

371. Rotenstreich Y, Belkin M, Sadetzki S, et al. Treatment With 9- cis ß-Carotene-Rich Powder in Patients With Retinitis Pigmentosa: A Randomized Crossover Trial. JAMA Ophthalmol 2013; 131: 1–8.

372. Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 2010; 127: 172–184.

373. Rotenstreich Y, Harats D, Shaish A, et al. Treatment of a retinal dystrophy, fundus albipunctatus, with oral 9-cis-{beta}-carotene. Br J Ophthalmol 2010; 94: 616–21.

374. Peltola K, Heinonen OJ, Näntö-Salonen K, et al. Oral lysine feeding in gyrate atrophy with hyperornithinaemia – A pilot study. J Inherit Metab Dis 2000; 23: 305–307.

375. Sipilä I, Rapola J, Simell O, et al. Supplementary Creatine as a Treatment for Gyrate Atrophy of the Choroid and Retina. N Engl J Med 1981; 304: 867–870.

376. Lee TKM, Clandinin MT, Hébert M, et al. Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial. Can J Ophthalmol 2010; 45: 514–9.

377. Rotenstreich Y, Belkin M, Sadetzki S, et al. Treatment with 9-cis ß-carotene-rich powder in patients with retinitis pigmentosa: a randomized crossover trial. JAMA Ophthalmol 2013; 131: 985–92.

378. Mehr E, Freíd A. El cuidado de la baja visión. 2a edición. Madrid: Organización Nacional de Ciegos Españoles (ONCE). Sección de acción social, 1995.

379. Binns AM, Bunce C, Dickinson C, et al. How effective is low vision service provision? A systematic review. Surv Ophthalmol 2012; 57: 34–65.

380. Fernandez Guardiola A, Sierra Jane I. Análisis de la patología ocular y de la adaptación de ayudas visuales en pacientes afectos de baja visión: revisión de 1.000 casos. Arch Soc Esp Oftalmol 2001; 76: 527–31.

381. Altpeter E, Mackeben M, Trauzettel-Klosinski S. The importance of sustained attention for patients with maculopathies. Vision Res 2000; 40: 1539–1547.

382. Schuchard R a. Adaptation to macular scotomas in persons with low vision. Am J Occup Ther Off Publ Am Occup Ther Assoc 1995; 49: 870–876.

383. Shah M, Zaman M, Khan M, et al. Visual rehabilitation of patients with stargardt’s disease. J Coll Physicians Surg Pakistan 2008; 18: 294–8.

384. Fonda G, Gardner LR. Characteristics and Low Vision, Corrections in Stargardt’s Disease. Ophthalmology 1985; 92: 1084–1091.

385. Paskowitz DM, LaVail MM, Duncan JL. Light and inherited retinal degeneration. Br J Ophthalmol 2006; 90: 1060–1066.

386. Radu R a, Mata NL, Bagla A, et al. Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt’s macular degeneration. Proc Natl Acad Sci U S A 2004; 101: 5928–5933.

387. Sparrow JR, Nakanishi K, Parish C a. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Investig Ophthalmol Vis Sci 2000; 41: 1981–9.

388. Mata NL, Weng J, Travis GH. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci U S A 2000; 97: 7154–9.

389. Scuderi G, Verboschi F, Domanico D, et al. Case Report Fixation Improvement through Biofeedback Rehabilitation in Stargardt Disease. Case Rep Med 2016; 2016: 1–4.

390. Vingolo EM, Salvatore S, Cavarretta S. Low-vision rehabilitation by means of MP-1 biofeedback examination in patients with different macular diseases: A pilot study. Appl Psychophysiol Biofeedback 2009; 34: 127–133.

391. Brilliant R, Ginsburg L. Rehabilitation of peripheral field defects. Chapter 12. In: Brilliant R (ed) Essentials of low visión practice. Boston: Butterworth heinemann, 1999.

392. Alexander KR, Fishman GA, Derlacki DJ. Intraocular light scatter in patients retinitis pigmentosa. Vision 1996; 36: 3703–9.

393. Grover S, Alexander KR, Choi DM, et al. Intraocular light scatter in patients with choroideremia. Ophthalmology 1998; 105: 1641–1645.

394. Rundquist J. Low Vision Rehabilitation of Retinitis Pigmentosa. Low Vis Rehabil Retin Pigment – Pract Reports 2004; 98: 718–724.

395. Van Den Berg TJ. Red glasses and visual function in retinitis pigmentosa. Doc Ophthalmol 1989; 73: 255–74.

396. Silver JH, Lyness a L. Do retinitis pigmentosa patients prefer red photochromic lenses? Ophthalmic Physiol Opt 1985; 5: 87–89.

397. Kuyk T, Elliott J, Fuhr P. Visual correlates of obstacle avoidance in adults with low vision. Optom Vis Sci 1998; 75: 174–82.

398. Weiss N. Low vision management of retinitis pigmentosa. J Am Optom Assoc 1991; 62: 42–52.

399. Somani S, Brent MH, Markowitz SN. Visual field expansion in patients with retinitis pigmentosa. Can J Ophthalmol 2006; 41: 27–33.

400. Fishman G a. When your eyes have a wet nose: The evolution of the use of guide dogs and establishing the seeing eye. Surv Ophthalmol 2003; 48: 452–458.

401. Hartong DT, Jorritsma FF, Neve JJ, et al. Improved mobility and independence of nightblind people using night-vision goggles. Investig Ophthalmol Vis Sci 2004; 45: 1725– 1731.

402. Hartong DT, Kooijman a. C. Night-vision goggles for night-blind subjects: Subjective evaluation after 2 years of use. Ophthalmic Physiol Opt 2006; 26: 490–496.

403. Friedburg C, Serey L, Sharpe LT, et al. Evaluation of the Night Vision Spectacles on patients with impaired night vision. Graefe’s Arch Clin Exp Ophthalmol 1999; 237: 125– 136.

404. Hoover KL. Visual acuity with the ITT Night Vision Aid for patients with night blindness. Am J Optom Physiol Opt 1983; 60: 762–8.

405. Mancil RM, Mancil GL, King E, et al. Improving nighttime mobility in persons with night blindness caused by retinitis pigmentosa: A comparison of two low-vision mobility devices. J Rehabil Res Dev 2005; 42: 471–486.

406. Spandau UH, Wechsler S, Blankenagel A. Testing night vision goggles in a dark outside environment. Optom Vis Sci 2002; 79: 39–45.

407. Kozlowski JM, Mainster MA, Avila MP. Negative-lens field expander for patients with concentric field constriction. Arch Ophthalmol 1984; 102: 1182–4.

408. Hoeft WW, Feinbloom W, Brilliant R, et al. Amorphic lenses: a mobility aid for patients with retinitis pigmentosa. Am J Optom Physiol Opt 1985; 62: 142–8.

409. Szlyk JP, Seiple W, Laderman DJ, et al. Use of bioptic amorphic lenses to expand the visual field in patients with peripheral loss. Optom Vis Sci 1998; 75: 518–24.

410. Laderman DJ, Szlyk JP, Kelsch R, et al. A curriculum for training patients with peripheral visual field loss to use bioptic amorphic lenses. J Rehabil Res Dev 2000; 37: 607–619.

411. Holm OC. A simple method for widening restricted visual fields. Arch Ophthalmol 1970; 84: 611–2.

412. Lowe J, Drasdo N. Using binocular field expander on a wide-field search task. Optom Vis Sci 1992; 69: 186–9.

413. Kennedy W, Rosten J, Young L, et al. A field expander for patients with retinitis pigmentosa: a clinical study. Am J Optom Physiol Opt 1977; 54: 744–55.

414. Drasdo N. Visual field expanders. Am J Optom Physiol Opt 1976; 53: 464–7.

415. Holm O. Visual field widening in retinitis pigmentosa [proceedings]. Acta Ophthalmol Suppl 1975; 125: 25–6.

416. Woods R, Giorgi R, Berson E, et al. Extended wearing trial of trifield lens device for ‘tunnel vision’. 2011; 18: 1492–1501.

417. Loshin DS, Juday RD. The programmable remapper: clinical applications for patients with field defects. Optom Vis Sci 1989; 66: 389–95.

418. Hoeft WW, Feinbloom W, Brilliant R, et al. Amorphic lenses: a mobility aid for patients with retinitis pigmentosa. Am J Optom Physiol Opt 1985; 62: 142–8.

419. Bowers AR, Luo G, Rensing NM, et al. Evaluation of a prototype Minified Augmented- View device for patients with impaired night vision. Ophthalmic Physiol Opt 2004; 24: 296–312.

420. Luo G, Woods RL, Peli E. Collision judgment when using an augmented-vision headmounted display device. Investig Ophthalmol Vis Sci 2009; 50: 4509–4515.

421. Peláez-Coca MD, Vargas-Martín F, Mota S, et al. A versatile optoelectronic aid for low vision patients. Ophthalmic Physiol Opt 2009; 29: 565–572.

422. Peláez-Coca MD, Sobrado-Calvo P, Vargas-Martín F. Optoelectronic aid for patients with severely restricted visual fields in daylight conditions. J Mod Opt 2011; 58: 1871– 1879.

423. Colombo E, Jaen M, Javier Santillán J. Iluminación y baja visión. . Sao Paulo, Brasil, 2006.

424. Park WL, Sunness JS. Red contact lenses for alleviation of photophobia in patients with cone disorders. Am J Ophthalmol 2004; 137: 774–775.

425. Jonsson ÅC, Burstedt MSI, Golovleva I, et al. Tinted contact lenses in Bothnia dystrophy. Acta Ophthalmol Scand 2007; 85: 534–539.

426. Haegerstrom-Portnoy G, Schneck ME, Verdon WA, et al. Clinical vision characteristics of the congenital achromatopsias. I. Visual acuity, refractive error, and binocular status. Optom Vis Sci 1996; 73: 446–56.

427. Terry RL. The use of tinted contact lenses in a case of congenital rod monochromatism. Clin Exp Optom 1988; 71: 188–90.

428. Brennan M, Cardinali G. The use of preexisting and novel coping strategies in adapting to age-related vision loss. Gerontologist 2000; 40: 327–334.

429. Horowitz a. The prevalence and consequences of vision impairment in later life. Top Geriatr Rehabil 2004; 20: 185–195.

430. McKinzie C, Reinhardt J, Benn D. Adaptation to Chronic Vision Impairment: Does African American or Caucasian Race Make a Difference? Res Aging 2009; 29: 144–162.

431. Chacon-Lopez H, Lopez-Justicia MD, Vervloed MPJ. Psychological and educational recommendations for working with young people with Retinitis Pigmentosa. Sch Psychol Int 2014; 35: 357–369.

432. DiNuzzo a R, Black S a, Lichtenstein MJ, et al. Prevalence [correction of prevalance] of functional blindness, visual impairment, and related functional deficits among elderly Mexican Americans. J Gerontol A Biol Sci Med Sci 2001; 56: M548–51.

433. Horowitz A. Depression and Vision and Hearing Impairments in Later Life. Generations 2003; 27: 32–38.

434. Horowitz A, Brennan M, Reinhardt J. Prevalence and Risk Factors for Self-Reported Visual Impairment Among Middle-Aged and Older Adults 2005. Res Aging 2005; 27: 307–326.

435. Reinhardt JP. The importance of friendship and family support in adaptation to chronic vision impairment. J Gerontol B Psychol Sci Soc Sci 1996; 51: P268–78.

436. Harsh M. Women Who Are Visually Impaired or Blind as Psychotherapy Clients: Women Ther 1993; 14: 55–64.

437. Furner S, Rudberg M, Cassel C. Medical Conditions Differentially Affect the Development of IADL Disability: Implications for Medical Care and Research. Gerontologist 1995; 35: 444–450.

438. McAuley E, Konopack JF, Motl RW, et al. Physical activity and quality of life in older adults: Influence of health status and self-efficacy. Ann Behav Med 2006; 31: 99–103.

439. Ormel J, Kempen G, Penninx B, et al. Chronic medical conditions and mental health in older people: disability and psychosocial resources mediate specific mental health effects. Psychol Med 1997; 27: 1065–77.

440. Reinhardt JP, Boerner K, Benn D. Predicting Individual Change in Support Over Time Among Chronically Impaired Older Adults. Psychol Aging 2003; 18: 770–779.

441. Verbrugge LM, Patrick DL. Seven chronic conditions: their impact on US adults’ activity levels and use of medical services. Am J Public Health 1995; 85: 173–82.

442. Vu HT V, Keeffe JE, McCarty C a, et al. Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol 2005; 89: 360–3.

443. Pinquart M, Pfeiffer JP. Perceived social support in adolescents with and without visual impairment. Res Dev Disabil 2013; 34: 4125–4133.

444. Codina B. Orientación espacial en personas con ceguera. In: Coco M, Herrera J (eds) Manual de Baja Visión y Rehabilitación Visual. Madrid: Editorial Médica Panamericana, 2015, pp. 300–320.

445. Crossland MD, Silver JH. Thirty years in an urban low vision clinic: changes in prescribing habits of low vision practitioners. Optom Vis Sci 2005; 82: 617–622.

446. Markowitz SN. Principles of modern low vision rehabilitation. Can J Ophthalmol / J Can d’Ophtalmologie 2006; 41: 289–312.

447. Jalali MD, Moussavi MS, Yazdi SAA, et al. Effectiveness of Rational Emotive Behavior Therapy on Psychological Well-Being of People with Late Blindness. J Ration Cogn Ther 2014; 32: 233–247.

448. Virgili G, Rubin G. Orientation and mobility training for adults with low vision. Cochrane database Syst Rev 2010; CD003925.

449. Gleeson M, Sherrington C, Lo S, et al. Can the Alexander Technique improve balance and mobility in older adults with visual impairments? A randomized controlled trial. Clin Rehabil 2015; 29: 244–60.

450. Ingraham C, Vernon M, Clemente B, et al. Sex education for deaf-blind youths and adults. J Vis Impair Blind 2000; 94: 756–61.

451. Codina B. Enseñanza de las habilidades de desplazamiento: desarrollo de los componentes perceptivo-motores y cognitivos. In: Alegre de la Rosa O (ed) Organización escolar y diversidad. Málaga: Ediciones Aljibe, 2006, pp. 401–438.

452. Berson EL, Hanson AH 3rd, Rosner B, et al. A two year trial of low protein, low arginine diets or vitamin B6 for patients with gyrate atrophy. Birth Defects Orig Artic Ser 1982; 18: 209–218.

453. Berson EL, Shih VE, Sullivan PL. Ocular findings in patients with gyrate atrophy on pyridoxine and low-protein, low-arginine diets. Ophthalmology 1981; 88: 311–315.

454. Kaiser-Kupfer MI, Caruso RC, Valle D. Gyrate atrophy of the choroid and retina. Arch Ophthalmol 1991; 109: 1539–48.

455. Kaiser-Kupfer MI, Caruso RC, Valle D. Gyrate atrophy of the choroid and retina. Arch Ophthalmol 2002; 120: 146–53.

456. Kaiser-Kupfer MI, Caruso RC, Valle D, et al. Use of an arginine-restricted diet to slow progression of visual loss in patients with gyrate atrophy. Arch Ophthalmol 2004; 122: 982–4.

457. McInnes RR, Arshinoff SA, Bell L, et al. Hyperornithinaemia and gyrate atrophy of the retina: improvement of vision during treatment with a low-arginine diet. Lancet 1981; 513–516.

458. Shih VE, Berson EL, Gargiulo M. Reduction of hyperornithinemia with a low protein, low arginine diet and pyridoxine in patients with a deficiency of ornithine-ketoacid transaminase (OKT) activity and gyrate atrophy of the choroid and retina. Clin Chim Acta 1981; 113: 243–251.

459. Valle D, Walser M, Brusilow SW, et al. Gyrate atrophy of the choroid and retina: amino acid metabolism and correction of hyperornithinemia with an arginine-deficient diet. J Clin Invest 1980; 65: 371–8.

460. Valle D, Walser M, Brusilow S, et al. Gyrate atrophy of the choroid and retina. Biochemical considerations and experience with an arginine-restricted diet. Ophthalmology 1981; 88: 325–330.

461. Kaiser-Kupfer MI, de Monasterio F, Valle D, et al. Visual results of a long-term trial of a low-arginine diet in gyrate atrophy of choroid and retina. Ophthalmology 1981; 88: 307– 310.

462. Wang T, Steel G, Milam a H, et al. Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina. Proc Natl Acad Sci U S A 2000; 97: 1224–9.

463. Berson EL, Rosner B, Sandberg MA, et al. Omega-3 intake and visual acuity un patients with retinitis pigmentosa on vitamin A. Arch Ophthalmol 2013; 130: 707–11.

464. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004; 122: 1297–305.

465. Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol 2004; 122: 1306–14.

466. Bayyoud T, Bartz-Schmidt KU, Yoeruek E. Long-term clinical results after cataract surgery with and without capsular tension ring in patients with retinitis pigmentosa: a retrospective study. BMJ Open 2013; 3: 1–6.

467. Reccia R, Scala A, Bosone G. Posterior chamber intraocular lens implantation in patients with retinitis pigmentosa. Doc Ophthalmol 1989; 72: 115–118.

468. Newsome D, Stark W, Maumenee I. Cataract extraction and intraocular lens implantation in patients with retinitis pigmentosa or Usher’s syndrome. Arch Ophtalmol 1986; 104: 852–854.

469. Kogure S, Iijima H. Preoperative evaluation by laser interferometry in cataractous eyes with retinitis pigmentosa. Jpn J Ophthalmol 1993; 37: 282–286.

470. Jackson H, Garway-Heath D, Rosen P, et al. Outcome of cataract surgery in patients with retinitis pigmentosa. Br J Ophthalmol 2001; 85: 936–938.

471. Fagerholm P, Philipson T. Cataract in retinitis pigmentosa An analysis of cataract surgery results and pathological lens changes. Acta Ophthalmol 1985; 63: 50–58.

472. Bastek J, Heckenlively J, Straatsma B. Cataract surgery in retinitis pigmentosa patients. Ophthalmology 1982; 89: 880–884.

473. Hayashi K, Hayashi H, Matsuo K, et al. Anterior capsule contraction and intraocular lens dislocation after implant surgery in eyes with retinitis pigmentosa. Ophthalmology 1998; 105: 1239–1243.

474. Figueroa-Wong LW, Suárez-tatá M, Peniche-moreno S, et al. Resultados visuales en pacientes con retinosis pigmentaria , operados de catarata con facoemulsificación e implante de lente intraocular. Rev Mex Oftalmol 2003; 77: 41–43.

475. Dikopf MS, Chow CC, Mieler WF, et al. Cataract extraction outcomes and the prevalence of zonular insufficiency in retinitis pigmentosa. Am J Ophthalmol 2013; 156: 82–88.

476. Casparis H, Lindsley K, Kuo IC, et al. Surgery for cataracts in people with age-related macular degeneration. Cochrane Database Syst Rev 2013; 6: CD006757.

477. Hooper CY, Lamoureux EL, Lim L, et al. Cataract surgery in high-risk age-related macular degeneration: a randomized controlled trial. Clin Experiment Ophthalmol 2009; 37: 570–576.

478. American Academy of OPhthalmology Cataract and Anterior Segment Panel. Preferred Practice Pattern Guideline. Cataract in the adult eye. San Francisco, CA, 2011.

479. Peralta J, Pastora N. Degeneraciones vitrorretinianas hereditarias. In: Oftalmología SE de (ed) Patología y Cirugía de la mácula. 2010.

480. Pendergast SD, Trese MT. Familial exudative vitreoretinopathy: Results of surgical management. Ophthalmology 1998; 105: 1015–1023.

481. Shukla D, Singh J, Sudheer G, et al. Familial exudative vitreoretinopathy (fevr). Clinical profile and management. J Ophthalmol 2003; 51: 323–328.

482. Carroll C, Papaioannou D, Rees A, et al. The clinical effectiveness and safety of prophylactic retinal interventions to reduce the risk of retinal detachment and subsequent vision loss in adults and children with Stickler syndrome: a systematic review. 2011. Epub ahead of print 2011. DOI: 10.3310/hta15160.

483. Ang A, Poulson A V., Goodburn SF, et al. Retinal Detachment and Prophylaxis in Type 1 Stickler Syndrome. Ophthalmology 2008; 115: 164–168.

484. Leiba H, Oliver M, Pollack A. Prophylactic laser photocoagulation in Stickler syndrome. Eye (Lond) 1996; 10: 701–708.

485. Monin C, Van Efferterre G, Andre-Sereys P, et al. [Prevention of retinal detachment in Wagner–Stickler disease. Comparative study of different methods. Apropos of 22 cases.]. J Fr Ophtalmol 1994; 17: 167–74.

486. Monin C, Allagui M, Larricart P, et al. [Prevention of non-traumatic retinal detachment by surgical cerclage. J Fr Ophtalmol 1993; 16: 247–53.

487. Fritsch D, Vallat M, Lagoutte F, et al. [Prevention of retinal detachment in Wagner- Stickler syndrome]. Bull Soc Ophtalmol Fr 1989; 89: 657–64.

488. Wilkinson C. Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment. Cochrane Database Syst Rev 2014; CD003170.

489. Ikeda T, Fujikado T, Tano Y. Combined tractional rhegmatogenous retinal detachment in familial exudative vitreoretinopathy associated with posterior retinal holes: Surgical therapy. Retina 1998; 18: 566–568.

490. Ikeda T, Fujikado T, Tano Y, et al. Vitrectomy for rhegmatogenous or tractional retinal detachment with familial exudative vitreoretinopathy. Ophthalmology 1999; 106: 1081– 5.

491. Bergen R, Glassman R. Familial exudative vitreoretinopathy. Ann Ophthalmol 1983; 15: 275–276.

492. Sobrin L, Berrocal AM, Murray TG. Retinal detachment 7 years after prophylactic schisis cavity excision in juvenile X-linked retinoschisis. Ophthalmic surgery, lasers & imaging 2003; 34: 401–402.

493. Aylward G. Optimal procedures for retinal detachment. In: Retinak textbook. 2006, pp. 2095–2105.

494. Schwartz SG, Flynn HW. Primary retinal detachment: scleral buckle or pars plana vitrectomy? Curr Opin Ophthalmol 2006; 17: 245–50.

495. Tsang Cw, Cheung BTO, Lam RF, Tsang Cw, Cheung BTO LR (2005). Primary 23- Gauge Vitrectomy for Rhegmatogenous. Retina 2008; 28: 1075–1081.

496. Acar N, Kapran Z, Altan T, et al. Primary 25-gauge sutureless vitrectomy with oblique sclerotomies in pseudophakic retinal detachment. Retina 2008; 28: 1068–1074.

497. Von Fricken M a, Kunjukunju N, Weber C, et al. 25-Gauge sutureless vitrectomy versus 20-gauge vitrectomy for the repair of primary rhegmatogenous retinal detachment. Retina 2009; 29: 444–50.

498. Miller DM, Riemann CD, Foster RE, et al. Primary repair of retinal detachment with 25- gauge pars plana vitrectomy. Retina 2008; 28: 931–936.

499. Han DP, Mohsin NC, Guse CE, et al. Comparison of pneumatic retinopexy and scleral buckling in the management of primary rhegmatogenous retinal detachment. Am J Ophthalmol 1998; 126: 658–668.

500. Schwartz SG, Kuhl DP, McPherson AR, et al. Twenty-year follow-up for scleral buckling. Arch Ophthalmol 2002; 120: 325–329.

501. Heimann H, Bartz-Schmidt KU, Bornfeld N, et al. Scleral Buckling versus Primary Vitrectomy in Rhegmatogenous Retinal Detachment. Ophthalmology 2007; 114: 2142– 2154.e4.

502. Arya A V, Emerson JW, Engelbert M, et al. Surgical management of pseudophakic retinal detachments: a meta-analysis. Ophthalmology 2006; 113: 1724–33.

503. Brazitikos PD, Androudi S, Christen WG, et al. Primary pars plana vitrectomy versus scleral buckle surgery for the treatment of pseudophakic retinal detachment: a randomized clinical trial. Retina 2005; 25: 957–64.

504. Lois N, Wong D. Pseudophakic retinal detachment. Surv Ophthalmol 2003; 48: 467– 487.

505. Abrams G, Azen S, McCuen B 2nd, et al. Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol 1992; 110: 770–9.

506. Tseng W, Cortez RT, Ramirez G, et al. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol 2004; 137: 1105–1115.

507. Jain N, Kozak J, Niziol L, et al. Vitrectomy Alone in the Management of Giant Retinal Tears. Ophthalmic Surgery, Lasers Imaging Retin 2014; 45: 421–427.

508. Cox SN, Hay E, Bird A. Treatment of Chronic Macular Edema With Acetazolamide. Arch Ophtalmol 1988; 106: 1190–5.

509. Moldow B, Sander B, Lund-andersen H. The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefe’s Arch Clin Exp Ophthalmol 1998; 236: 881–9.

510. Fishman G, Gilbert L. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophtalmol 1989; 107: 1445–52.

511. Chung H, Hwang J, Kim J, et al. Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis pigmentosa. Retina 2006; 26: 922–7.

512. Apushkin M, Fishman G, Grover S, et al. Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina 2007; 27: 1112–1118.

513. Orzalesi N, Pierrottet C, Porta A, et al. Long-term treatment of retinitis pigmentosa with acetazolamide A pilot study. Graefe’s Arch Clin Exp Ophthalmol 1993; 231: 254–256.

514. Apushkin M a, Fishman G a, Janowicz MJ. Monitoring cystoid macular edema by optical coherence tomography in patients with retinitis pigmentosa. Ophthalmology 2004; 111: 1899–904.

515. Thobani A, Fishman G. The use of carbonic anhydrase inhibitors in the retreatment of cystic macular lesions in retinitis pigmentosa and X-linked retinoschisis. Retina 2011; 31: 312–15.

516. Pinckers A, Cruysberg J. Acetazolamide in dominant cystoid macular dystrophy. Ophthalmic Paediatr 1993; 14: 95–9.

517. Fishman G a., Gilbert LD, Anderson RJ, et al. Effect of Methazolamide on Chronic Macular Edema in Patients with Retinitis Pigmentosa. Ophthalmology 1994; 101: 687– 693.

518. Gilbert LD, Fishman GGA, Glenn AM, et al. Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa. Arch Ophtalmol 1993; 111: 1640–6.

519. Shahidi M, Fishman G, Ogura Y, et al. Foveal thickening in retinitis pigmentosa patients with cystoid macular edema. Retina 1994; 14: 243–7.

520. Grover S, Fishman G, Fiscella R, et al. Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Retina 1997; 17: 222–31.

521. Ikeda Y, Hisatomi T, Yoshida N, et al. The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2012; 250: 809–14.

522. Ikeda Y, Yoshida N, Notomi S, et al. Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 2013; 97: 1187–91.

523. Grover S, Apushkin M a, Fishman G a, et al. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 2006; 141: 707.

524. Fishman G a, Apushkin M a. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 2007; 91: 743–5.

525. Genead M, Fishman G. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol 2010; 128: 1146–1150.

526. Pacella E, Arrico L, Santamaria V, et al. Chlorhydrate Versus Acetazolamide in the Management of Chronic Macular Edema in Patients with Retinitis Pigmentosa: Description of Three Case Reports. Opthalmology eye Dis 2014; 6: 21–26.

527. Guiffre G. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 2006; 142: 707.

528. Grover S. Topical Dorzolamide for the treatment of Cystoid Macular Edema in patients with retinitis pigmentosa Reply. Am J Ophthalmol 2005; 142: 707–8.

529. Passo M, Palmer E, Van Buskirk E. Plasma timolol in glaucoma patients. Ophthalmology 1984; 91: 1361–3.

530. García Sánchez J, Honrubia López F, García Feijóo J, et al. Diagnóstico y tratamiento del glaucoma del ángulo abierto. LXXXIX Ponen la Soc Española Oftalmol 2013; 10: 283–306.

531. Ghajarnia M, Gorin M. Acetazolamide in the treatment of X-linked retinoschisis maculopathy. Arch Ophthalmol 2007; 125: 571–573.

532. Apushkin MA, Fishman GA. Use of Dorzolamide for patients with x-linked retinoschisis. Retina 2006; 26: 741–745.

533. Genead M, Mcanany J, Fishman G. Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia. Retina 2012; 32: 826–33.

534. Khandhadia S, Trump D, Menon G, et al. X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype. Eye 2011; 25: 922–8.

535. Giusti C, Forte R, Vingolo E. Deflazacort treatment of cystoid macular edema in patients affected by Retinitis Pigmentosa: a pilot study. Eur Rev Med Pharmacol Sci 2002; 6: 1– 8.

536. Ozdemir H, Karacorlu M, Karacorlu K. Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol … 2005; 83: 248–51.

537. Scorolli L, Morar M, Meduri A, et al. Treatment of Cystoid Macular Edema in Retinitis Pigmentosa With Intravitreal Triamcinolone. Arch Ophtalmol 2007; 125: 759–64.

538. Wang C, Hu J, Bernstein P, et al. Intravitreal injection of triamcinolone acetonide for macular due to retinitis pigmentosa and other retinal diseases. Adv Exp Med Biol 2006; 572: 309–314.

539. Gokce G, Sobaci G, Durukan A, et al. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion. Postgr Med 2013; 125: 51–8.

540. Bressler NM, Edwards AR, Beck RW, et al. Exploratory analysis of of diabetic retinopathy progression through 3 years in a randomized clinical trial comparing intravitreal triamcinolone with focal/grid photocoagulation. Arch Ophthalmol 2009; 127: 1566–71.

541. Conti SM, Kertes PJ. The use of intravitreal corticosteroids, evidence-based and otherwise. Curr Opin Ophthalmol 2006; 17: 235–244.

542. Luthra S, Alberto R, Luigi S, et al. Bilateral optic neuropathy and intraretinal deposits after pars plana vitrectomy. Indian J Ophthalmol 2013; 63: 72–4.

543. Group DRR. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447–1450.

544. Gómez-Ulla F, Abraldes MJ, Basauri E, et al. Guías de práctica clínica de la SERV: manejo de las oclusiones venosas de la retina. Arch Soc Esp Oftalmol 2010; 85: 294– 309.

545. Mirshahi A, Shenazandi H, Lashay A, et al. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina 2010; 30: 254–259.

546. Ramezani A, Esfandiari H, Entezari M, et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion. Acta ophthalmol 2014; 92: e530–e539.

547. Pareja Ríos a, López Galvez M. Manejo de las complicaciones oculares de la diabetes. Retinopatía Diabética y Edema Macular. 2015.

548. Srour M, Querques G, Leveziel N, et al. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2013; 251: 1501–6.

549. Yuzbasioglu E, Artunay O, Rasier R, et al. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. Curr Eye Res 2009; 34: 231–7.

550. Melo GB, Farah ME, Aggio FB. Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand 2007; 85: 461–3.

551. Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. J Ocul Pharmacol Ther 2009; 25: 545–50.

552. Heckenlively J, Newsome D, Blacharski P. Grid photocoagulation for macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 1987; 103: 161–6.

553. García-Arumí J, Martinez V, Sararols L, et al. Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa. Ophthalmology 2003; 110: 1164–9.

554. Batioglu F, Ozmert E, Parmak N, et al. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. 27.

555. Sodi A, Murro V, Caporossi O, et al. Long-Term Results of Photodynamic Therapy for Choroidal Neovascularization in Pediatric Patients with Best Vitelliform Macular Dystrophy. 2015; 26: 168–74.

556. Kapoor KG, Bakri SJ. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization due to Sorsby macular dystrophy. J Ocul Pharmacol Ther 2013; 29: 444–447.

557. Andrade RE, Farah ME, Costa R. Photodynamic Therapy With Verteporfin for Subfoveal Choroidal Neovascularization in Best Disease. Am J Ophthalmol 2003; 136: 1179–1181.

558. Batioglu F, Ozmert E, Suren E, et al. Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Best’s Vitelliform Macular Dystrophy. J Med Cases 2012; 3: 250–253.

559. Cennamo G, Cesarano I, Vecchio EC, et al. Functional and Anatomic Changes in Bilateral Choroidal Neovascularization Associated with Vitelliform Macular Dystrophy After Intravitreal Bevacizumab. J Ocul Pharmacol Ther 2012; 28: 643–6.

560. Frennesson CI, Wadelius C, Nilsson SEG. Best vitelliform macular dystrophy in a Swedish family: genetic analysis and a seven-year follow-up of photodynamic treatment of a young boy with choroidal neovascularization. Acta Ophthalmol 2014; 92: 238–242.

561. Querques G, Bocco MCA, Soubrane G, et al. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macukar dystrophy. Acta Ophthalmol 2008; 246: 694–5.

562. Velazquez-Villoria D, Badia CM, Quera JR, et al. Bevacizumab intravítreo en neovascularización coroidea asociada a enfermedad de Best. Arch Soc Esp Oftalmol 2015; 89: 405–407.

563. Campos Arcos M, Díaz Cascajosa J. Ranibizumab intravítreo como tratamiento de membrana neovascular coroidea asociada a la distrofia macular viteliforme o enfermedad de Best. In: 44 Congrés de la Societat Catalana d’Oftalmologia. 2003.

564. Sisk R a, Berrocal AM, Albini T a, et al. Bevacizumab for the treatment of pediatric retinal and choroidal diseases. Ophthalmic Surg Lasers Imaging 2010; 41: 582–592.

565. Celea C, Pop M, Avidis-Zamfiroiu N, et al. Evolution of Choroidal Neovascular Membrane in Best Disease after Single Intravitreal Bevacizumab. Case Report. MAEDICA- a Journa Clin Med 2015; 10: 61–64.

566. Peiretti E, Klancnik JJ, Spaide R, et al. Choroidal neovascularization in sorsby fundus dystrophy treated with photodynamic therapy and intravitreal triamcinolone acetonide. Retina 2005; 25: 377–9.

567. Querques G, Bocco MCA, Soubrane G, et al. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt’s disease. Graefes Arch Clin Exp Ophthalmol 2008; 246: 319–21.

568. Kim HH, Carvounis PE, Bc H, et al. Photodynamic therapy for bilateral subfoveal choroidal neovascularization complicating stargardt macular dystrophy. Retin Cases Br Reports 2008; 2: 6–8.

569. Malik A, Sood S, Narang S. Successful treatment of choroidal neovascular membrane in retinitis pigmentosa with intravitreal bevacizumab. Int Ophthalmol 2010; 30: 425–428.

570. Palejwala N V, Lauer AK, Weleber RG. Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab. Clin Ophthalmol 2014; 8: 1675–9.

571. Tiosano L, Jaouni T, Averbukh E, et al. Bevacizumab treatment for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy. Eur J Ophthalmol 2014; 24: 890–6.

572. Prieto-Calvo E, Torrón-Fernández Blanco C, Egea-Estopiñán C, et al. Ranibizumab intravítreo en neovascularización coroidea secundaria a distrofia foveomacular viteliforme del adulto. Arch Soc Esp Oftalmol 2012; 87: 149–152.

573. Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, et al. Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy. Graefe’s Arch Clin Exp Ophthalmol 2011; 249: 455–458.

574. Mimoun G, Caillaux V, Querques G, et al. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: oneyear results. Retina 2013; 33: 513–521.

575. Sohn E, Patel P, MacLaren R, et al. Responsiveness of Choroidal Neovascular Membranes in Patients With R345W Mutation in Fibulin 3 (Doyne Honeycomb Retinal Dystrophy) to Anti–Vascular Endothelial Growth Factor Therapy. Arch Ophthalmol 2011; 129: 1626–8.

576. Parodi MB, Iacono P, Cascavilla M, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Investig Ophthalmol Vis Sci 2010; 51: 4358–4361.

577. Empeslidis T, Vardarinos a, Deane J, et al. Intravitreal ranibizumab in the treatment of butterfly-shaped pattern dystrophy associated with choroidal neovascularization: a case report. Case Rep Ophthalmol 2012; 3: 77–82.

578. Miller S, Bresnick G, Chandra S. Choroidal neovascular membrane in Best’s vitelliform macular dystrophy. Am J Ophthalmol 1976; 82: 252–5.

579. Moss H, Epley KD, Tripathy K, et al. Best Disease. Best Disease http://eyewiki.aao.org/Best_Disease (2014, accessed 22 February 2016).

580. Wormald R, Evans J, Smeeth L, et al. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007; CD002030.

581. Heckenlively JR, Yoser SL, Friedman LH, et al. Clinical findings and common symptoms in retinitis pigmentosa. Am J Ophthalmol 1988; 105: 504–11.

582. Vingolo EM, Salvatore S, Stagnitti F. Visual acuity changes in retinitis pigmentosa during pregnancy. Int J Gynecol Obstet 2009; 105: 269.

583. Ahuja AK, Dorn J, Caspi A, et al. Blind subjects implanted with the argus II retinal prosthesis are able to improve preformance in a spatial-motor task. Br J Ophthalmol 2011; 95: 539–43.

584. Ammann F, Klein D, Franceschetti A. Genetic and epidemiological investigations on pigmentary degeneration of the retina and allied disorders in Switzerland. J Neurol Sci 1963; 2: 183–96.

585. Haim M, Holm N V, Rosenberg T. Prevalence of retinitis pigmentosa and allied disorders in Denmark. I Main results. Acta Ophthalmol 1992; 70: 178–86.

586. Jin X, Qu LH, Meng XH, et al. Detecting genetic variations in hereditary retinal dystrophies with next-generation sequencing technology. Mol Vis 2014; 20: 553–60.

587. Damen GWJ a, Krabbe PFM, Kilsby M, et al. The Usher lifestyle survey: maintaining independence: a multi-centre study. Int J Rehabil Res 2005; 28: 309–320.

588. Figueiredo M, Chiari B, Goulart B. Communication in deafblind adults with Usher syndrome: retrospective observational study. CoDAS 2013; 3: 319–324.

589. Hyvärinen L. Implications of deafblindness on visual assessment procedures: considerations for audiologists, ophthalmologists, and interpreters. Trends Amplif 2007; 11: 227–32.

590. Bittner AK, Edwards L, George M. Coping strategies to manage stress related to vision loss and fluctuations in retinitis pigmentosa. Ophthometry 2010; 81: 461–8.